Yi-Xiang Wang - research works

Pearson correlation and maximum entropy (MaxEnt) were used to analyze correlations and identify spatial risk levels.

The results showed that hypertension prevalence was negatively correlated with grain intake (r=-0.600, p=0.002) and poultry consumption (r=-0.504,p=0.010) and alcohol use showed the highest contribution among behavioural variables (39.2%) in the MaxEnt model.

Among ten medications for NIU, adalimumab accounted for the highest number of AEs reports (N=5,842), followed by infliximab (N=1,199), prednisone (N=749), and methotrexate (N=427).

Common AEs were observed in the present study.

For instance, AEs of infections (N=293) and endocrine disorders (N=47) were reported in prednisone.

We also found several AEs which had not been reported in NIU patients before, with splenomegaly as an example (ROR 95% CI lower bound: 4.66; IC025: 1.35; P<0.001).

Papillary thyroid cancer was the most common NTRK-positive tumor (49.74%) and harbored all 3 NTRK subtypes.

Among NTRK-positive samples, NTRK3 (74.87%) was the most prevalent subtype, followed by NTRK1 (23.59%).

ETS variant transcription factor 6 (ETV6) was the most frequent fusion partner identified in 122 of 195 cases.

Particularly, the detection sensitivity for NTRK3 fusions was significantly enhanced and reached 95.89%.

The oJIA model required 4 joint pairs (elbows, knees, ankles, MCP1); although its correlation with systemic activity was limited by localized disease, it showed excellent numerical agreement with the comprehensive score, supporting its use for monitoring.

The growth hormone intervention group ( n = 124) showed significantly higher annualized growth velocity than the nutritional support group ( n = 124) across all age groups ( p < 0.05).

Multivariate logistic regression revealed that duration of growth hormone therapy was the independent predictor of treatment efficacy (OR = 4.45, 95% CI: 1.53-12.93, p = 0.006).

Significant differences were observed in the distribution of frailty status across physical activity levels, with a clear linear trend (all p < 0.001).

Sensitivity analyses indicated a moderate negative correlation between physical activity score and total frailty score (rho = -0.454, p < 0.001), which remained significant in linear regression models.

This association persisted after further adjustment for disease burden, disease-system count, and disease-system indicators.

The mean age was 56.5 ± 15.5 years, and 82.1% had unilateral disease.

Median diagnostic delay was 33 months; 20.9% required repeat aqueous taps.

Glaucoma rose from 30.3% to 62.0% and ECCD loss from 27.8% to 57.0% during follow-up.

Kaplan-Meier analysis showed a median time of 9 years from symptom-onset to manifest glaucoma.

Eight patients (61.5%) developed optic neuritis (ON) secondary to VZV infection, and five patients (38.5%) suffered from acute retinal necrosis (ARN), which was caused by VZV ( n = 2), HSV-1 ( n = 2), and PRV ( n = 1).

Bilateral involvement occurred in 46.2% (6/13) of patients.

At the disease nadir, 46.2% of patients (6/13) presented with no light perception (NLP).

All patients received antiviral therapy, 11 of whom (84.6%) were treated with intravenous antiviral agents.

Higher urinary calprotectin levels were observed in the severe AKI group at any time point (All P<0.001).

The AUC of the clinical model increased from 0.693 (95%CI, 0.633 to 0.754) to 0.730 (95%CI, 0.677 to 0.784) upon adding urinary calprotectin, the NRI was 0.337 (P<0.001) and the IDI was 0.055 (P<0.001).

Unfavorable outcomes occurred in 420 patients (39.3%).

Higher AAR was associated with poor outcomes in the overall cohort (adjusted OR 1.34, 95% CI: 1.07-1.66).

However, significant effect modification by disease type was observed (P for interaction = 0.001).

Conversely, AAR showed no significant prognostic value in ICH ( p = 0.746) or aSAH ( p = 0.810).

Patients with MetS-OA experienced slightly longer hospital stays and incurred higher median total hospitalization charges, exceeding those without MetS-OA by $1,445.50.

In-hospital mortality did not differ significantly between groups.

MetS-OA was also associated with a higher likelihood of postoperative complications, including acute myocardial infarction, severe malnutrition, acute cerebrovascular disease, postoperative delirium, acute respiratory distress syndrome, prolonged mechanical ventilation, urinary tract infections, acute renal failure, and lower limb nerve injury.

All patients presented with unilateral involvement: 25 with right OAS and 41 with left OAS.

However, the initial ocular presentations varied: blurred vision was reported in all patients, with 63.64% of them suffering from severe visual function impairment (best-corrected visual acuity, BCVA < 20/200), followed by ophthalmoplegia in 56 patients (84.85%), and headache/facial numbness in 40 patients (60.61%).

The overall correction rate was 18.0% ± 14.0%, with 56.1% of patients achieving a Cobb angle below 40°, and 39.0% showing improvement greater than 10°.

Multivariate analysis revealed that daily brace-wearing time was an independent predictor of correction rate (each additional hour increased the correction rate by 1.88%, P = 0.003).

The four core domains of the SRS-22r quality-of-life questionnaire (function/activity, pain, self-image, and mental health) demonstrated significant improvement, and treatment satisfaction was high at final follow-up.

Patient motivation showed a strong positive correlation with wearing time ( r = 0.654).

They underwent comprehensive clinical assessment, amyloid PET, and tau PET.

For Alzheimer's disease (AD) diagnosis, tau PET demonstrated high sensitivity (97.8%) and specificity (95.4%), showing substantial agreement with amyloid PET.

In patients clinically diagnosed with non-AD disorders, tau PET led to a significantly higher rate of diagnostic change compared with amyloid PET (p = 0.018).

Overall accuracy was high (primary area under the curve (AUC) 0.923; ADNI 0.904).

The optimal biomarker shifted from tau-centric markers in LO to Aβ42/Aβ40 in EO.

Opposing-direction associations were observed for p-tau217%, which correlated negatively with onset age in AD but positively in Non-AD cognitive impairment.

In an exploratory analysis, baseline p-tau217 was associated with longitudinal cognitive decline, numerically greater in EO though based on a small subgroup.

Laparoscopy-assisted LDLT was successfully performed in all 13 pediatric patients.

The mean total operative time was 478 min (range, 315-615 min), the median portal vein clamping time was 47 min (range, 33-107 min), the average time required to remove the liver was 229 min (range, 115-357 min), and the median cold ischemia time was 85 min (range, 29-214 min).

The intraoperative course for all the recipients was uneventful.

A total of 106 patients completed the study (53 per group).

No significant differences were observed in other adverse events, including nausea and vomiting.

Median change in VA (IQR) as per-protocol from baseline-to-week 24 was 40 (28-70) letters in Arm-A (n = 24) versus 13 (0-66) letters in Arm-B (n = 25); corresponding to a between-group difference of 24 letters, adjusted for baseline, in favour of early vitrectomy (p = 0.139).

Higher rate of non-serious adverse events observed in Arm-B (68%) compared to Arm-A (47%), with higher incidence of retinal detachment 8 cases (24%) in Arm-B versus 2 cases in Arm-A (6.7%).

EFV improved risk discrimination over FRS, CACS, obstructive CAD, and ischemia burden (all P<0.05).

In the stratified analyses, CACS (aHR =2.88; P=0.017) and obstructive CAD (aHR =3.69; P=0.005) predicted MACE in low-to-intermediate FRS patients, whereas EFV (aHR =3.13; P=0.020) and ischemia burden (aHR =4.67; P=0.005) were only associated with MACE in high-risk FRS patients.

Aberrant splicing explained most candidate-group diagnoses, including variants misclassified by in silico predictors such as SpliceAI.

14% of protein-truncating variants predicted to undergo nonsense-mediated decay (NMD) escaped degradation, highlighting the functional limits of current predictions.

The most frequent among them was a recurrent synonymous East Asian founder mutation in ECHS1, accounting for seven cases.

Interestingly, across 233 pathogenic variants associated with aberrant RNA phenotypes compiled from this study and prior reports, half were noncoding and half were coding variants.

SHAP analysis identified luteinizing hormone, body mass index, TW3 RUS bone age, and insulin-like growth factor 1 as the leading contributors to predicted suboptimal-response risk.

We noted no significant differences in age, body mass index, tumor stage, pathologic type, surgical duration, or postoperative hospital stay between the two groups (P>0.05).

Postoperative complication rates were similar, with 24.3% in the study group and 17.4% in the traditional group (P>0.05).

In addition, the median tumor size in the study group was 51 mm (IQR, 45-57.5 mm), compared with 46 mm (IQR, 42-50 mm) in the traditional group (P<0.05).

The CUSUM curve peaked after the 12th case, indicating a transition from learning to proficient phases, with significantly reduced surgical times in the proficient phase (P<0.05).

The systemic features, including recurrent oral ulceration, multiform skin lesions and genital ulceration were weighted as 4 points, 3 points and 2 points, respectively.

Primary assessment was based on ocular features alone.

An ocular score ≥5 supported a BU diagnosis in patients without signs of granulomatous uveitis or evidence of sarcoidosis or syphilis.